Trial Profile
Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy of Denosumab 60mg sc Every 3 Months in Patients With Erosive Osteoarthritis of the Interphalangeal Finger Joints
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Jul 2023
Price :
$35
*
At a glance
- Drugs Denosumab (Primary) ; Calcium supplements; Vitamin D
- Indications Osteoarthritis
- Focus Proof of concept; Therapeutic Use
- 03 Jun 2023 Primary endpoint has been met. (Evaluate the change in the negative evolution in GUSS scores in the target IP joints from baseline to week 24)
- 03 Jun 2023 Results from main study and open label extension study , presented at the 24th Annual Congress of the European League Against Rheumatism
- 27 May 2021 This trial has been completed in Belgium, according to European Clinical Trials Database record.